- Etamsylate
-
- $0.00 / 1kg
-
2024-08-23
- CAS:2624-44-4
- Min. Order: 1kg
- Purity: 99.0%
- Supply Ability: 1tons
- Etamsylate
-
- $230.00 / 1kg
-
2024-08-23
- CAS:2624-44-4
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 1000000tons
|
| Etamsylate Basic information |
| Etamsylate Chemical Properties |
Melting point | 125° | density | 1.3441 (rough estimate) | refractive index | 1.5060 (estimate) | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | solubility | Very soluble in water, freely soluble in methanol, soluble in anhydrous ethanol, practically insoluble in methylene chloride. | form | Solid | color | White to Pale Red | Merck | 14,3722 | Stability: | Hygroscopic | InChI | InChI=1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3 | InChIKey | HBGOLJKPSFNJSD-UHFFFAOYSA-N | SMILES | C1(S(=O)(=O)O)=CC(=CC=C1O)O.N(CC)CC | CAS DataBase Reference | 2624-44-4(CAS DataBase Reference) | EPA Substance Registry System | Ethamsylate (2624-44-4) |
RTECS | DB6145000 | HS Code | 2921.19.6190 | HazardClass | IRRITANT | Toxicity | LD50 i.v. in mice, rats: 800, 1350 mg/kg (Esteve) |
| Etamsylate Usage And Synthesis |
Chemical Properties | White Solid | Uses | Hemostatic;prostaglandin synthesis inhibitor | Uses | Haemostatic / Anti Coagulant | Definition | ChEBI: Etamsylate is a sulfonic acid derivative and an organosulfur compound. | Mechanism of action | Etamsylate is an antihaemorrhagic and vasoprotective agent. It increases platelet adhesiveness and capillary vascular wall resistance, thereby reducing capillary exudation and blood loss.
| Clinical Use | Short-term treatment of blood loss in menorrhagiaProphylaxis of surgical bleeding (unlicensed) | Side effects |
Significant: Hypotension (parenteral). Rarely, severe hypersensitivity reaction, including anaphylaxis. Blood and lymphatic system disorders: Parenteral: Rarely, neutropenia, agranulocytosis, thrombocytopenia. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain or discomfort. General disorders and administration site conditions: Asthenia (parenteral). Rarely, fever. Musculoskeletal and connective tissue disorders: Rarely, arthralgia. Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Rarely, thromboembolism (parenteral).
| Metabolism | Etamsylate is excreted unchanged, mainly in the urine. |
| Etamsylate Preparation Products And Raw materials |
|